Diabetic Neuropathy
Aegera Initiates Phase 1 Clinical Trial of AEG33773 - a Small Molecule in Development for Diabetic Neuropathic Pain
Published in Medical Letter on the CDC and FDA, April 6th, 2008
Aegera Therapeutics announced the initiation of a Phase 1, first-in-man, clinical trial for AEG33773, a novel, orally bioavailable small molecule in development for the treatment of painful diabetic neuropathy. The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of AEG33773 using a randomized, double blind, placebo controlled, single ascending dose design in healthy male volunteers.
Aegera completed a comprehensive pre-clinical development program on AEG33773, culminating in regulatory clearance from Health Canada and treatment of a first patient, in less than 12 months.
"We are extremely excited about the potential...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Biopharmaceuticals
OMRIX Biopharmaceuticals Provides Update on its Fibrin Patch Product Candidate - Bone Research
New bone research reported from Yale University, Medical Department - Breast Cancer Screening
Findings in breast cancer screening reported from University of California - Breast Implants
Studies conducted at S.V.M. Maharaj et al on breast implants recently published - Cryotherapy
Recent findings in cryotherapy described by M.H. Gold and colleagues - Drug Delivery
FDA Classifies Medtronic's Physician Communication Related to Inflammatory Mass Formation from Intrathecal Drug Therapy - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
